Related Experiment Video
Updated: May 11, 2026
08:46
A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma (DIPG)
Published on: March 7, 2017
Management of diffuse pontine gliomas in children: recent developments
Rejin Kebudi1, Fatma Betul Cakir
1Istanbul University Cerrahpasa Medical Faculty Pediatric Hematology-Oncology, P.C: 34090, Millet Street, Capa, Istanbul, Turkey, rejinkebudi@yahoo.com.
Paediatric Drugs
|May 31, 2013
Summary
Diffuse intrinsic pontine gliomas (DIPGs) have a poor prognosis in children, with limited survival despite standard treatments. Emerging research into DIPG biology and novel therapies offers hope for improved outcomes.
Area of Science:
- Pediatric Oncology
- Neuro-oncology
- Cancer Biology
Background:
- Diffuse intrinsic pontine gliomas (DIPGs) are aggressive pediatric brain tumors with a dismal prognosis.
- They represent 10-15% of pediatric brain tumors but are a leading cause of cancer-related death in children.
- Current standard therapy, radiotherapy, offers only transient improvement.
Purpose of the Study:
- To review recent advances in understanding DIPG biology.
- To discuss systemic therapies administered in conjunction with or after radiotherapy.
- To explore novel therapeutic options for DIPG.
Main Methods:
- Review of recent clinical studies and research on DIPG.
- Analysis of data from biopsy and autopsy samples.
- Evaluation of systemic therapies and novel treatment strategies.
Main Results:
- Despite numerous clinical trials, prognosis for DIPG has not significantly improved.
- Increasing knowledge of DIPG biology is emerging from sample research.
- Systemic therapies are being investigated in various treatment sequences.
Conclusions:
- Multimodal and multitargeted therapies hold potential for improving DIPG prognosis.
- Continued research into DIPG biology and treatment is crucial.
- Novel therapeutic approaches are needed to combat this devastating disease.
